Izgrev

Hydrochlorothiazide and Irbesartan, the active ingredients in Izgrev, are a thiazide diuretic and an angiotensin II receptor blocker presented as oral tablets for systemic use. They are prescribed to lower elevated blood pressure in adult patients with hypertension and to reduce the risk of cardiovascular complications. The combination targets fluid balance and vascular tone, providing synergistic blood pressure control. GNH USA supplies Izgrev as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with consistent quality assurance and regulatory compliance across EU markets.

Izgrev is used to manage hypertension, a condition characterized by chronically elevated arterial pressure. Hypertension: reduces systolic and diastolic blood pressure, helping to lower the risk of cardiovascular events in adult patients.

Like all antihypertensive agents, Izgrev may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Electrolyte imbalance (e.g., low potassium or sodium): mild disturbances that may cause muscle cramps or fatigue. - Dizziness or light‑headedness: especially after the first doses or when standing quickly. - Increased urination: due to the diuretic component. - Mild headache: transient and often resolves with continued therapy.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Angio‑edema: swelling of face, lips, tongue or throat requiring immediate medical attention.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor electrolytes: regular blood tests for sodium, potassium and creatinine are recommended. - Assess renal function: patients with impaired kidneys may need dose adjustment. - Avoid use in severe hepatic impairment: limited data available. - Caution in elderly: increased sensitivity to blood pressure changes. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Izgrev can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia. - Lithium: increased lithium levels and toxicity. - Dual renin‑angiotensin system blockers (ACE inhibitors, other ARBs): additive hypotensive effect. - NSAIDs: may reduce antihypertensive efficacy and affect renal function.

Moderate Interactions (Monitor Closely): - Corticosteroids: may enhance sodium loss. - Antidiabetic drugs: diuretic effect may alter glucose control. - Beta‑blockers: additive blood pressure lowering.